Houston doctors get approval for low-cost COVID vaccine abroad

green light

Drs. Maria Elena Bottazzi and Peter Hotez got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

2 Houston powerhouses deploy game-changing COVID-19 worldwide vaccine

a good shot

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston health care organizations team up for the 'people's vaccine'

COVID Collaboration

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

ClassPass, which recently opened a Houston location, has launched a new tool for users to find their closest vaccine location. Photo courtesy of ClassPass

Tech company launches COVID-19 vaccine finder in Houston

there's an app for that

A global tech company that recently opened a local office in Houston has announced a major upgrade to its app — and it's now available in Houston.

ClassPass, a network of fitness and wellness partners, now has Houston vaccine centers searchable within the app and website. Members can find their closest vaccine center and get important information — like hours and address — as well as how to contact the locations; however, users aren't able to book directly through ClassPass.

"We are in a global health crisis and every company should be helping to support relief and vaccination efforts however they can. Using the ClassPass platform to connect members with vaccine centers is a natural extension of our technology and a way that we can contribute to curbing the spread of COVID-19," says Jeff Bladt, vice president of pricing and inventory, in a news release.

"We have deep knowledge of how to help people find accurate and up-to-date information on local businesses after routing millions of users to fitness and wellness locations across 30 countries," he adds.

Users can search for COVID vaccine locations online or through the app. Photo courtesy of ClassPass

The new search option has been rolled out already in in Austin and Dallas, as well as Boston, Chicago, Denver, Miami, New York City and Washington, D.C.

"The process of finding a vaccination appointment can be challenging and many people don't know where to start," says Dr. Vin Gupta, a critical care pulmonologist, health policy expert, and NBC News Medical Analyst, in the release.

"I was thrilled to hear that ClassPass, a high touch app that has already trained people how to search for vital health information, is leveraging their platform to make it easier to identify vaccine sites and secure appointments," he continues. "Anything that can address this information gap is critical in getting more people vaccinated."

ClassPass quickly pivoted when the pandemic hit last year, and now all 41,500 fitness, wellness, and beauty partners on the app have been asked to provide updated details on their COVID policies. ClassPass also worked with 5,000 top studios around the world to add digital classes as an option.

In March, Houston-based ClassPass exec, Rachel Moctron, joined the Houston Innovators Podcast to discuss this pivot and the new Houston office. Listen to it below.


This new guide helps streamline vaccine sites and eligibility information in one place. Photo courtesy of CVS Health

New app gives good shot at finding COVID-19 vaccination in Houston

HELP WITH HEALTHCARE

Are you frustrated by the hoops you're jumping through to get a COVID-19 vaccination? The GoodRx drug-price-comparison app has stepped in to help.

GoodRx just rolled out a guide so you can learn about the COVID-19 vaccine, track its availability, and set up a vaccination appointment in Houston or elsewhere in Texas.

"Vaccine information has been fragmented and availability unclear, so GoodRx has built the go-to destination for all Americans to track the vaccine rollout locally," the company says in a statement.

GoodRx is collecting data from more than 15,000 vaccination sites and is monitoring the country's 70,000 pharmacies as well as state-specific sites to update appointment availability. New information is added as it becomes available.

Among other things, the GoodRx guide tells you who's eligible for vaccinations where you live, who's next in line, and how you can make a vaccination appointment. You can even sign up to receive text messages that alert you when vaccination eligibility changes in your area.

This news comes as Texas Gov. Greg Abbott has reopened the state and lifted the mask mandate — which could put Houstonians at even greater risk.

Meanwhile, throughout Texas, the recent winter storm, power outages, and water shortages hampered the ability to distribute COVID-19 vaccines. As of March 3, Harris County shows some 351,063 confirmed COVD cases, according to most-recent data, and 2,297,878 cases statewide. Information about the Texas vaccination plan is available on the Department of State Health Services website.

------

This article originally ran on CultureMap.

Fort Bend is now a COVID-19 vaccine hub. Photo by Matthew T. Carroll/Getty Images

This Houston suburb is the newest COVID-19 vaccine hub in the region

Help in Fort Bend

A major Houston suburb is the newest major COVID-19 vaccine hub in the region. Fort Bend County has received an additional 8,000 vaccines, county judge KP George announced on February 9 at a press conference.

That means the county is officially an vaccine hub and will receive regular doses of inoculations, George added. Registration is available at the Fort Bend County website.

During the news conference, George said Fort Bend County had been officially designated as a vaccine hub, meaning the county will now be receiving regular doses of the vaccine.

In keeping with statewide mandates, vaccinations are open to those who are in phases 1A or 1B, although those in the next phases will be eligible at a later date, according to the press conference.

This news comes as the Greater Houston area has seen the emergence of the South African COVID-19 variant, as well as two mutations of the UK strain, as CultureMap previously reported.

Texas Gov. Greg Abbott has also ordered a mega vaccine site in the Houston area that promises to deliver some 5,000 to 6,000 inoculations per day. Houston has also received thousands of new vaccines this week.

Meanwhile, for now, COVID hospitalizations are seeing a downturn, according to reports.

For more information on Fort Bend County vaccinations, visit www.fbchealth.org or call 832-471-1373.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH researcher lights up at-home COVID-19 testing with glow-in-the-dark materials

get lit

A Houston-based research team is tapping glow-in-the-dark materials to upgrade at-home rapid COVID-19 testing.

Researchers at the University of Houston have been rethinking the lateral flow assay (LFA) test used for at-home COVID-19 diagnostics. The traditional method indicates the sample's results with colored lines.

“We are making those lines glow-in-the-dark so that they are more detectable, so the sensitivity of the test is better,” says Richard Willson, a professor at the University of Houston, in a UH news release. He previously created a smartphone-based diagnostics app.

Willson's inspiration came from a familiar and nostalgic method — the glow-in-the-dark stars in a child's bedroom. In Willson's case, it was his daughter's bedroom, and within a few days his team of students and postdocs was designing a test featuring glowing nanoparticles made of phosphors.

The team evolved into a spin-off company called Clip Health, originally founded as Luminostics by two of the researchers. The operation is again evolving with new glowing applications.

“In this new development, there are two tricks. First, we use enzymes, proteins that catalyze reactions, to drive reactions that emit light, like a firefly. Second, we attached those light-emitting enzymes onto harmless virus particles, along with antibodies that bind to COVID proteins,” says Willson in the Royal Society of Chemistry’s journal Analyst.

The test now also can be read with a smartphone app. The group is also entertaining additional tests for other diseases.

“This technology can be used for detecting all kinds of other things, including flu and HIV, but also Ebola and biodefense agents, and maybe toxins and environmental contaminants and pesticides in food,” says Willson.

In addition to Willson, the original technology was explained in a paper with co-authors:

  • Katerina Kourentzi, University of Houston research associate professor of chemical and biomolecular engineering
  • Jacinta Conrad, Frank M. Tiller Associate Professor of Chemical and Biomolecular Engineering,
  • UH researchers Maede Chabi, Binh Vu, Kristen Brosamer, Maxwell Smith, and Dimple Chavan

Researcher Richard Willson says he was inspired by the glow-in-the-dark scars on his daughter's bedroom ceiling. Photo via UH.edu

Houston energy giant makes moves on emissions with Astros deal, new tech in the Permian Basin

Houston-based energy company Occidental is capturing a ton of attention with its carbon capture initiative.

Occidental’s carbon capture subsidiary, 1PointFive, recently said it’s developing a carbon capture and sequestration hub on a 55,000-acre site along the Gulf Coast in Southeast Texas. The hub will be able to hold about 1.2 million metric tons of carbon dioxide.

The Bluebonnet Hub, expected to be operating in 2026, will be located in Chambers, Liberty, and Jefferson counties near coastal refineries, chemical plants, and manufacturing facilities. Chambers County is the Houston metro area.

“This hub is located between two of the largest industrial corridors in Texas so captured CO2 can be efficiently transported and safely sequestered,” says Jeff Alvarez, president of sequestration at 1PointFive. “Rather than starting from scratch with individual capture and sequestration projects, companies can plug into this hub for access to shared carbon infrastructure.”

Home run on emissions

Another development at 1PointFive involves the Houston Astros baseball team.

The Astros recently agreed to buy CO2 removal credits from 1PointFive’s carbon capture plant being built in Ector County, whose county seat is Odessa. Under this deal, CO2 captured by the company’s equipment will be sequestered in underground saline reservoirs that aren’t affiliated with oil and gas production.

Over the next three years, the Astros will use the removal credits to help the team achieve a carbon-neutral footprint at Minute Maid Park.

“We remain committed to continuous improvement of our stadium for our fans, and purchasing carbon removal credits is an important investment for us,” Marcel Braithwaite, senior vice president of business operations for the Astros, says in a news release.

Progress in the Permian Basin

Furthermore, 1PointFive is making progress on its carbon capture plant being developed in West Texas’ Permian Basin. The company recently tapped Orlando, Florida-based Siemens Energy to supply two compressors for the plant, which is set to capture more than 500,000 metric tons of CO2 per year.

Vicki Hollub, president and CEO of Occidental, says in a news release that the Permian Basin plant will help meet the Paris Agreement’s Paris climate change goals and reduce global emissions.

The Permian Basin facility, with an estimated price tag of $800 million to $1 billion, is on track to open by late 2024.

The real estate challenges, opportunities Houston faces as hub for biotech, according to expert

guest column

In the decade prior to COVID, when it came to early stage biotech companies establishing a foothold in Houston, space-wise, there were only a handful of options to choose from. Because of specialized equipment needs, including in many cases, the requirement for vent hoods, multiple sinks, and 24/7 air-conditioned space, traditional flex type projects were not a ready-made option. UH’s Technology Bridge offered those amenities, and while it worked for some, it was not intended as a permanent business home. Most emerging biotech firms found space that was a partial fit, and modified it to work (at their cost).

Houston’s Rise on the National Stage

For a variety of reasons, including its broad talent pool, lower cost of operations, and more favorable business climate, Houston has continued to attract biotech companies from other states. Following on the heels of new and expanding life science firms, and a supportive ecosystem, investor interest in building and purchasing properties to meet their specialized requirements has been a natural result. Unlike traditional office occupiers, lab users need physical space, and are not candidates for a hybrid or work from home model.

TMC Proximity Premium

Land costs inside Loop 610 have historically trended higher than suburban alternatives. For this reason, the newest projects completed near TMC like Helix Park and the planned Bioport are focused on much larger firms and institutions with the ability to commit to a long lease term and pay a premium rent. A second tier of real estate investors has also entered the market, however, purchasing nearby 80’s vintage projects, upgrading them, and repurposing the space to meet demand from mid-size or less creditworthy biotech companies. Existing small to mid-size tenants currently housed in these projects can expect to see bumps in both rent and expenses.

As an alternative to close-in options, but within a reasonable drive of the TMC, Pearland, Sugar Land and Stafford have increasingly become a location choice for biotech firms. Pearland’s EDC has targeted life science companies needing custom-built manufacturing facilities with economic incentives for some time. Lonza, Merit Medical, and formerly St. Paul-based Cardiovascular Systems are just three recent examples touted on their website.

Planning for Affordable Lab Space Options

Management teams for early stage companies are stretched thin, and are not always prepared for the time and money it takes to find and equip office/lab space.

Not all suburban landlords want to incur the sizeable costs for a customized build out, which can range between $40 and $200 per square foot. Entrepreneurs are also surprised by the 4-6 months of lead time it typically takes to identify space options, negotiate a lease, and permit and build the improvements (including the unexpected costs of bringing an older project in compliance with current energy and building codes).

However, with realistic expectations about these challenges, the good news is that once settled into a facility that is a fit, Houston’s emerging biotech companies can thrive and grow.

------

Julie King is President of NB Realty Partners. She has mentored and provided commercial real estate advice to technology, biotech, and early-stage companies for over 23 years.

View All Listings